Ultratech just lately posted its This fall Outcomes with robust QoQ efficiency each on the Income and Internet revenue entrance, following which Jeferries has elevated its goal on the Inventory
Brokerage Goal and Rationale
Jefferies has maintained a Purchase name on Ultratech Cement shares following its Q4FY25 outcomes with a goal worth of Rs. 14,000, which is an Upside of 17.89 % from the present market worth of Rs. 11,875. The sooner goal given by Jefferies was Rs. 13,265.
The brokerage states that in Q4FY25 outcomes, Ultratech had proven good EBTDA progress after a steady decline up to now three quarters. Jefferies additionally expects enchancment in unit EBITDA for the acquired capacities from latest acquisitions, and the Q1 of FY26 might see advantages from the latest uptick in pricing.
Monetary Highlights
The corporate reported a 12.94 % YoY improve in income from Rs. 20,419 Crore in Q3FY24 to Rs. 23,063 Crore in Q3FY25. On a QoQ foundation, the corporate reported a rise of 29.72 % in income from Rs. 17,779 Crore within the earlier quarter.
Their Internet revenue noticed a rise of 9.56 % YoY from Rs. 2,259 Crore to Rs. 2,475 Crore for a similar interval. On a QoQ foundation, the corporate reported a powerful improve of 81.58 % in Internet revenue from Rs. 1,363 Crore within the earlier quarter.
In regards to the Firm
UltraTech Cement Restricted is the most important cement firm in India and part of the Aditya Birla Group. It manufactures a variety of development supplies, together with gray cement, white cement, and ready-mix concrete.
The corporate has a powerful presence throughout India and likewise operates in worldwide markets. Recognized for its deal with high quality, innovation, and sustainability, UltraTech performs a key position in infrastructure and actual property growth and continues to increase its footprint by means of strategic investments and diversification into allied constructing materials segments.
Written By Abhishek Das
Disclaimer
The views and funding suggestions expressed by funding specialists/broking homes/ranking companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Buyers should subsequently train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the creator usually are not accountable for any losses brought about on account of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
